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Introduction: Chronic inflammation plays a key role in the patho-
genesis of malignant pleural mesothelioma (MPM) as a result of
asbestos exposure. Biomarkers of systemic inflammation have been
shown to predict the natural history of MPM; however, this obser-
vation lacks independent validation. Our aim was to compare the
prognostic performance of three inflammation-based biomarkers in
predicting overall survival (OS) in MPM.
Methods: In patients with histologically proven MPM, the inflam-
mation-based prognostic scores modified Glasgow Prognostic Score
(mGPS), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-
lymphocyte ratio were studied and compared with the European
Organization for the Research and Treatment of Cancer Prognostic
Score (EPS) and other known potential prognostic factors such as
gender, histologic subtype, Eastern Cooperative Oncology Group
performance status, and baseline blood parameters.
Results: A total of 171 MPM patients presenting to Imperial
College NHS Trust were studied. In univariate analyses, the follow-
ing parameters were predictors of OS: female gender (p  0.03),
epithelioid histology (p  0.03), normal C-reactive protein (p 
0.03), baseline white blood cell count 8.3  109/liter (p  0.04),
EPS (p  0.003), mGPS (p  0.001), NLR (p  0.006), and
platelet-to-lymphocyte ratio (p  0.03). Multivariate survival anal-
ysis confirmed the mGPS (hazard ratio  2.6; p  0.001) and NLR
(hazard ratio  2.0; p  0.008), but not the EPS, as independent
predictors of OS. Tissue expression of Ki-67 (p  0.001) and
vascular endothelial growth factor (p  0.001) was higher in a
subgroup of patients with high-risk inflammatory scores.
Conclusions: The mGPS and NLR are externally validated prog-
nostic indices in patients with MPM and correlate with sustained
neoangiogenesis and increased proliferative index.
Key Words: Malignant mesothelioma, Prognosis, NLR, mGPS,
EORTC score.
(J Thorac Oncol. 2012;7: 587–594)
Malignant pleural mesothelioma (MPM) is a highly lethaltumor whose pathogenesis intimately correlates with
occupational or environmental exposure to asbestos fibers.
Despite a generalized ban on asbestos usage in most coun-
tries, the incidence and mortality from MPM is expected to
steadily increase in the next few years as a result of the
prolonged interval between asbestos exposure and the clinical
presentation of the disease.1 Because of the aggressive bio-
logic behavior of MPM, patient selection is crucial to im-
prove clinical outcomes. Eligibility to radical surgery is
limited to patients with early stage disease and intact cardio-
respiratory function; however, pleural decortication or extra-
pleural pneumonectomy has demonstrated a limited survival
benefit when used alone,2 and multimodal treatments inte-
grating radiation or systemic therapy have gained importance
in MPM.3 Platinum-based chemotherapy in combination with
pemetrexed yields the highest tumor response rates, and its
beneficial impact on patient survival and quality of life has
made it the systemic regimen of choice for MPM in both
the neoadjuvant and the palliative setting.4 However, the
delicate context of a short-life expectancy in conjunction
with potential side effects and only modest survival benefit
offered by the currently available treatments belies the
importance of a case-by-case risk-benefit assessment be-
fore any active treatment is administered.5 The identifica-
tion of prognostic determinants is, therefore, needed to
stratify patients into distinct risk categories and optimize
the provision of the currently available treatments, both in
the radical and palliative setting.6
A number of clinicopathologic features have been
proven to predict prognosis in MPM. Sarcomatoid differen-
tiation, elevated platelet and white blood cell (WBC) count,
and more advanced performance status (PS) have been rec-
ognized to reflect a more aggressive disease course.7,8 In an
attempt to standardize the prognostic assessment in MPM,
some of these clinically significant variables have been in-
corporated into coherent prognostic models. The European
Organization for the Research and Treatment of Cancer
Prognostic Score (EPS) has been devised to subcategorize
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patients into favorable or adverse prognostic groups based on
patient’s age and PS, presence and subtype of histologic
diagnosis, and WBC count at presentation.9 The Cancer and
Leukemia Group B score is a more complex system that
incorporates the presence of nonepithelial histology, weight
loss or chest pain, high platelet and WBC count, low hemo-
globin, high serum lactate dehydrogenase, advanced age, and
PS.10 The reliability of these prognostic models has been
strengthened by a process of validation in independent patient
cohorts.11 However, despite having generated some scientific
interest in the past, these scores are rarely used outside the
specific context of clinical trials.
The presence of a systemic inflammatory reaction in
patients with a diagnosis of cancer is deemed to reflect the
release of cytokines by the tumor itself or a host response
toward the tumor. Besides being involved in the pathogenesis
of cancer-related cachexia and nutritional decline, systemic
inflammation has been shown to predict clinically meaningful
outcomes such as overall and recurrence-free survival as well
as response to systemic treatment.12 Several inflammation-
based prognostic scoring systems have been devised to quan-
tify systemic inflammation from a clinical standpoint. These
include the neutrophil-to-lymphocyte ratio (NLR) and the
platelet-to-lymphocyte ratio (PLR), both of which reflect full
blood count derangements induced by the acute phase reac-
tion,13 while the modified Glasgow Prognostic Score (mGPS)
uses raised circulating C-reactive protein (CRP) and hy-
poalbuminemia.14 Convincing evidence supports the role of
tumor-produced proinflammatory cytokines in the progres-
sion of MPM.15 However, despite having been extensively
studied in several solid tumor types, the prognostic impact of
systemic inflammation has been relatively unaddressed in
MPM. Recently, the independent prognostic value of the
NLR, an inflammatory-related biomarker, was qualified in a
single-center study of patients with a diagnosis of MPM
undergoing systemic treatment in the context of phase II/III
clinical trials.16 Interestingly, NLR status could efficiently
subdivide patients into two distinct categories with a survival
difference of more than 10 months observed, whereas the
EPS did not retain independent prognostic value, casting
doubt on its predictive ability. Although Kao et al. qualified
the NLR as a predictor of overall survival (OS) in MPM,
statistical validation of its prognostic power was not carried
out, a crucial step before this biomarker can enter the routine
clinical arena. In addition, the single-center nature of this
study in conjunction with a patient population composed
mostly of clinical trial patients (i.e., with generally better PS)
may limit the generalizability of this observation.17 More-
over, currently, it is unknown which inflammatory-related
score best predicts survival, as a comparative assessment of
their predictive ability has never been performed in patients
suffering from MPM. The aim of this study is, therefore, to
assess the prognostic role of NLR, PLR, and mGPS in MPM.
Furthermore, in a subset of patients, we sought to determine
whether a relationship existed between systemic inflamma-
tion and tissue expression of proliferation and angiogenesis
biomarkers.
PATIENTS AND METHODS
Patient Population
Patients with a histologically proven diagnosis of MPM
presenting to the Imperial College NHS Healthcare Trust
between 1993 and 2011 were included in the study. We
identified 202 patients, from which cases with a positive
history of inflammatory disease (n  3), second primary
tumor (n  2), active infection (n  4), or insufficient
follow-up data (n  22) were excluded, to give a total
number of patients meeting the inclusion criteria of 171.
Clinical variables such as demographic data and staging
information were collected along with the complete blood
picture, albumin, and CRP. Patients were staged according to
International Mesothelioma Interest Group guidelines18
where possible. Because of the known inaccuracy of radio-
logic tumor staging, classes I–II and III–IV were grouped
together.19 The mGPS was calculated as described in previ-
ous studies.20 Briefly, patients with both a normal albumin
(35 g/liter) and CRP (10 mg/liter) were allocated a score
of 0. Patients in whom only one of these abnormalities was
present were allocated a score of 1, whereas those with both
abnormal CRP and albumin were given a score of 2. The
NLR was calculated by dividing the absolute neutrophil count
by the absolute lymphocyte count. NLR  5 was considered
elevated as described previously.21 The same calculation was
applied to derive the PLR, with 300 being the cutoff for
positivity, in accordance with the previously published liter-
ature.22 The following parameters were considered as poten-
tial prognostic factors: gender, PS (0 versus 1), histologic
subtype (epithelioid versus nonepithelioid), EPS, Interna-
tional Mesothelioma Interest Group stage, baseline WBC and
platelet count, CRP, albumin, and difference in hemoglobin
relative to 160 g/liter in men and 140 g/liter in women.23 The
EPS was derived as described previously and categorizes
patients into good versus poor prognostic groups according to
male gender, probable or possible histologic diagnosis, sar-
comatoid differentiation, PS 1, and WBC 8.3  109/
liter.24 OS was calculated from the time of the biopsy to that
of death or last follow-up. All the laboratory parameters were
collected before the biopsy. The cutoff values adopted to
categorize laboratory values are reported in Table 1 and
justified as to their prognostic value by previously published
evidence.16,23,24 Survival status was updated as of the August
2011. The study was approved by the Local Research Ethics
Committee.
Immunohistochemistry
Twenty patients were selected at random from the
database and stratified into two subgroups (n 10) according
to their inflammatory score: group A were patients with both
NLR 5 and mGPS 0 or 1 and group B consisted of patients
with NLR 5 and mGPS of 2. The median survival of
patients in group A was 25.9 months and group B was 3.6
months. After review of hematoxylin and eosin slides by a
board certified senior pathologist with more than 10 years
expertise in pulmonary pathology (F.M.), paraffin-embedded
tissue samples from representative blocks were cut into
4-m-thick sections, deparaffinized in xylene and graded
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alcohols, and subsequently rehydrated. Immunostaining for
Ki-67 (Leica Microsystems, Germany 1:800 dilution) and
vascular endothelial growth factor (VEGF; Santa Cruz, CA,
1:750 dilution) was performed using the Bond Max Auto-
stainer (Leica Microsystems, Germany) after appropriate an-
tigen unmasking.25 Appropriate positive controls were as-
sessed simultaneously using human tonsil and breast
carcinoma specimens as per manufacturer’s instructions. To
further validate the specificity of the reaction, omission of the
primary antibody was carried out in parallel, which resulted
in negative staining in all cases. VEGF immunopositivity was
scored accounting to both the percentage of positive cells
(ranging from 0 to 100) and the intensity of the signal,
defined as weak (1), medium (2), or strong (3). Percentage of
positive cells and intensity of staining were multiplied to-
gether giving rise to a composite immunohistochemical score
ranging from 0 to 300, as described earlier.26 The Ki-67
labeling index was expressed as the percentage of immuno-
positive nuclei from a minimum of 500 nuclei in at least five
microscopic fields. All the immunohistochemical staining
were independently examined by two observers (F.M. and
D.J.P.) blinded to outcomes. Consensus was reached between
the two scorers in any case of discordance.
Statistical Analysis
Pearson 2 test was used to assess for any associations
between clinicopathologic variables. Differences in VEGF
expression scores and proliferative index were assessed using
the Mann-Whitney U test. Kaplan-Meier statistics and log-
rank test were used to study the impact of the different
clinical factors associated with survival using univariate anal-
ysis. The independent prognostic value of each significant
factor was subsequently explored on multivariate analysis
using a stepwise backward Cox proportional hazard model.
Variables with a p value greater than 0.10 were removed from
the model. A p value of 0.05 was considered as being
significant. Statistical analysis was performed using SPSS
statistical package version 11.5 (SPSS Inc., Chicago, IL) and
GraphPad PRISM (GraphPad Software, Inc., La Jolla, CA).
RESULTS
Patient Demographics
The baseline patient characteristics are shown in Table
1. The majority was male (84%) and had a diagnosis of stage
III/IV disease (47%). Seventy patients (41%) had received
frontline systemic therapy. Seventy-two (42%) patients re-
ceived best supportive care. Treatment data were not avail-
able for 46 (17%) patients. At the time of analysis, 138 (86%)
patients had died, and the median OS was 9.7 months (95%
confidence interval [CI]  8.111.4).
Although baseline bloods were available for all pa-
tients, albumin was only available for 158 patients and CRP
for 148 patients. Full clinical staging was only available for
128 patients. EPS was available for 142 patients; 83 patients
(59%) had good risk; and 59 patients (41%) were of poor risk.
TABLE 1. Relationship between Inflammatory Scores and Baseline Clinicopathologic Variables in MPM
Baseline
Characteristic
NLR <5,
n (%)
NLR >5,
n (%) p
PLR <300,
n (%)
PLR >300,
n (%) P
mGPS 0,
n (%)
mGPS 1,
n (%)
mGPS 2,
n (%) p
Gender
Male 94 (86) 49 (79) 98 (88) 45 (75) 25 (83) 30 (88) 65 (83) 0.8
Female 15 (14) 13 (21) 0.3 13 (12) 15 (25) 0.03 5 (17) 4 (12) 13 (17)
PS
ECOG 0 36 (39) 12 (25) 31 (33) 12 (25) 14 (67) 12 (46) 12 (17) 0.001
ECOG 1 56 (61) 36 (75) 0.1 62 (67) 36 (75) 0.9 7 (33) 14 (54) 58 (83)
Histologic type
Epithelioid 73 (72) 38 (72) 80 (78) 38 (59) 23 (79) 27 (84) 46 (67) 0.1
Nonepithelioid 29 (28) 15 (28) 1.0 22 (22) 15 (41) 0.01 6 (21) 5 (16) 23 (33)
Platelet counts
(109/liter)
400 79 (72) 27 (43) 90 (81) 16 (27) 27 (90) 21 (62) 38 (49) 0.001
400 30 (28) 35 (57) 0.001 21 (19) 44 (73) 0.001 3 (10) 13 (31) 40 (51)
Baseline white cell
count (109/liter)
8.3 61 (56.0) 14 (22.6) 53 (47.7) 22 (37) 19 (63) 15 (44) 29 (46) 0.01
8.3 48 (44.0) 48 (77.4) 0.001 58 (52.3) 38 (63) 0.16 11 (37) 19 (56) 49 (64)
Hemoglobin difference
(g/liter)
10 24 (22.2) 11 (18.0) 27 (24.5) 8 (14) 15 (50) 9 (27) 6 (8) 0.001
10 84 (77.8) 50 (82.0) 0.6 83 (75.5) 51 (86) 0.1 15 (50) 25 (73) 71 (92)
Stage
I–II 34 (40) 14 (33) 35 (40) 13 (33) 11 (48) 9 (39) 20 (31) 0.3
III–IV 52 (60) 28 (67) 0.6 53 (60) 27 (67) 0.5 12 (52) 14 (61) 44 (69)
NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; mGPS, modified Glasgow Prognostic Score; ECOG PS, Eastern Cooperative Oncology Group
performance status.
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Inflammatory Markers and Baseline
Characteristics
Sixty-two patients (36%) of patients had an NLR 5,
which was significantly associated with baseline raised plate-
let counts. A PLR greater than 300 was seen in 60 patients
(35%) and was associated with male gender and nonepithe-
lioid subtype. The majority of patients had an abnormal
mGPS (66%), which was associated with worse PS, high
white cell count, high platelet count, and a greater than 10
g/liter difference in hemoglobin at baseline (Table 2).
Prognostic Variables Associated with Survival
Univariate analysis variables that predict for poor OS
included male gender (p  0.03), nonepithelioid histologic
subtype (p  0.03), PS  1 (p  0.007), high-risk EPS
(p  0.003; Figure 1A), baseline WBC count 8.3 
109/liter (p  0.04), NLR  5 (p  0.006), PLR  300
(p  0.03), CRP  10 mg/liter (p  0.03), albumin 35
g/liter (p  0.03), and mGPS  1 (p  0.001; Table 2).
Multivariate analysis revealed mGPS (hazard ratio  2.6; 95%
CI  1.64.2; p  0.001) and NLR (hazard ratio  2.0; 95%
CI  1.63.2; p  0.008) as independent predictors of OS.
OS rates at 1 year from diagnosis were 72, 35, and 17%
in patients with an mGPS of 0, 1, and 2, respectively, whereas
the 2-year survival rate was 29% for mGPS 0, 17% for mGPS
1, and 4% for mGPS 2 (Figure 1B). Similarly, the 1-year
survival rate for patients with an NLR  5 was 39% versus
26% for those with an NLR  5, whereas the 2-year survival
TABLE 2. Univariate and Multivariate Analysis of Prognostic Factors of Overall Survival
Univariate Analysis Multivariate Analysis
Variable n  171 Hazard Ratio (95% CI) p Hazard Ratio (95% CI) p
Sex (male/female) 143/28 1.7 (1.1–2.9) 0.03a
Histologic type (epithelioid/nonepithelioid) 101/42 1.5 (1.0–2.2) 0.03a
ECOG PS (0/1) 42/87 1.7 (1.1–2.5) 0.007a
EPS (low/high risk) 74/53 1.8 (1.2–2.6) 0.003a
Stage (I–II/III–IV) 48/80 1.2 (0.8–1.7) 0.48
Baseline WCC (109/liter) (8.3/8.3) 69/90 1.6 (1.2–2.3) 0.04a
Hemoglobin difference (g/liter) (10/10) 33/124 1.4 (0.9–2.2) 0.1
Treatment status (chemonaive/chemotherapy) 61/71 1.3 (0.9–1.9) 0.2
Baseline platelet counts (109/liter) (400/400) 97/62 1.4 (1.0–1.9) 0.07
NLR (5/5) 99/60 1.6 (1.1–2.3) 0.006a 2.0 (1.6–3.2) 0.008a
PLR (300/300) 101/58 1.5 (1.0–2.1) 0.03a
CRP (mg/liter) (10/10) 32/105 2.0 (1.3–3.1) 0.03a
Albumin (g/liter) (35/35) 81/66 1.5 (1.0–2.1) 0.03a
mGPS (0/1/2) 25/31/76 2.6 (1.7–3.9) 0.001a 2.6 (1.6–4.2) 0.001a
a Associations reaching statistical significance.
EPS, European Organization for the Research and Treatment of Cancer Prognostic Score; CI, confidence interval; WCC, white blood cell count; NLR, neutrophil-to-lymphocyte
ratio; PLR, platelet-to-lymphocyte ratio; mGPS, modified Glasgow Prognostic Score; ECOG PS, Eastern Cooperative Oncology Group performance status; CRP, C-reactive protein.
FIGURE 1. Kaplan-Meier survival curves for patients affected by malignant pleural mesothelioma stratified by staging system:
(A) European Organization for the Research and Treatment of Cancer (EORTC) Score; (B) modified Glasgow Prognostic Score
(mGPS); (C) neutrophil-to-lymphocyte ratio (NLR).
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rate was 13% versus 7% for NLR 5 and 5, respectively
(Figure 1C).
Association between Inflammatory Scores and
Tumor Proliferation and Angiogenesis
Tissue specimens obtained from patients in group B
had a significantly higher proliferative index compared with
those in group A (median nuclear count 55.5 versus 8.5, p 
0.001; Figure 2A). Likewise, a significantly increased VEGF
immunopositivity was observed in group B compared with
group A (median immunohistochemical score 225.0 versus
60.0, p  0.001; Figure 2B). Representative tissue sections
for each group are shown in Figure 3. The clinicopathologic
features of the selected cases are summarized in Table 3.
DISCUSSION
The ability to accurately predict prognostic information
has been the focus of research in MPM over the past few years.
Several models have been developed, each one including pa-
rameters reflecting respiratory symptoms, baseline pathologic
factors, and tumor stage. Unfortunately, none of these clinical
staging methods is considered ideal, and despite the increasing
number of comparative studies published, there is no consen-
sus as to the optimal staging system. As a sustained inflam-
matory response plays a key role in the pathogenesis of
MPM, we compared the utility of three widely used inflam-
mation-based prognostic scores in determining OS in a het-
erogeneous group of patients with MPM.
There is an increasing evidence in the literature sup-
porting the association between inflammatory markers and
the overall prognosis in a wide variety of cancers.16,27–29
Previous reports have shown that the NLR is a predictor of
outcome in MPM; however, this has only been investigated in
a single-center retrospective study solely of patients under-
going systemic treatment.16 In our analysis, male gender,
nonepithelioid histologic subtype, poor PS, low risk EPS,
increased WBC count, and the inflammatory markers NLR,
PLR, CRP, albumin, and mGPS 1 were shown to be
predictive of worse OS on univariate analysis. However, only
NLR and mGPS qualified as a true independent predictor of
survival on multivariate analysis. mGPS was able to stratify
patients groups with a survival differences of 8 months
between mGPS 0 and 1 (18.7 versus 10.5), and 11 months
between mGPS 0 and 2 (18.7 versus 7.3). The survival
difference was smaller between patients with NLR 5 and
NLR 5 (3 months). To our knowledge, this is the first
study to independently validate the prognostic role of
mGPS and NLR in a large cohort of patients presenting
FIGURE 2. Distribution of the proliferative index (A) and
vascular endothelial growth factor (VEGF) expression values
(B) across the two studied groups (n  10 each). Differences
in medians were tested using the Mann-Whitney U test.
FIGURE 3. Expression of Ki-67 and VEGF by
immunohistochemistry in patients with low risk
(NLR5 and mGPS of 0–1, Group A) versus
high risk inflammatory scores (NLR 5 and
mGPS of 2, Group B). A primary mesothelioma
specimen with low proliferative index (5%;
Panel A); and focal VEGF expression (Histo-
score  60; Panel C) is shown. A tumour speci-
men with elevated proliferative index (72%,
Panel B) and high VEGF expression (Histo-
score  300, Panel D) is shown. Original mag-
nification, 200.
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consecutively with a diagnosis of MPM. Furthermore, the
baseline characteristics of our patient cohort were compa-
rable with a previous phase III study in MPM in terms of
baseline patient characteristics and median survival.4
Therefore, although the cohort data were collected retro-
spectively, it is representative of patients with MPM pre-
senting to an Oncology Department.
Interestingly, in our multivariable screening of prog-
nostic indicators, two simple inflammation-based parameters,
the mGPS and NLR, performed better than the EPS, whose
clinical use in the prognostic assessment of MPM had ini-
tially been endorsed as a stratifying system to facilitate
patient selection in clinical trials,24 but more recently ques-
tioned in further published reports.16 Our results are consis-
tent with the study by Kao et al. who reported that an elevated
NLR not only predicted OS, but in those patients where
raised NLR normalized after one cycle of chemotherapy,
outcome was better than those in whom NLR remained
persistently elevated.16 The main difference between the
study by Kao et al. and this report pertains to the study
population. Kao et al. only considered those patients receiv-
ing systemic treatment, whereas we considered consecutive
patients presenting to clinic regardless of treatment status. In
general, it is well recognized that patients with good PS tend
to be offered systemic therapy both in a trial and clinical
setting.17 It is possible, therefore, that the study cohort in the
article by Kao et al. may have had a better overall PS than
those in our cohort, 42% of whom did not receive any
treatment. This may account for the difference in OS ob-
served between NLR groups in the two studies.
Given the pathologic role of chronic inflammation in
the development of MPM,30 our results that inflammatory-
based biomarkers are predictive of survival are not surprising.
Moreover, we showed that both NLR and mGPS correlate
significantly with a number of adverse clinicopathologic
parameters such as increased platelet counts and WBC, ane-
mia, and more advanced PS, suggesting that both inflamma-
tory scores are predictive of a more aggressive clinical
behavior. To further reinforce this concept, we demonstrated
that derangement of proinflammatory indices reflects an in-
crease in both tumor cell proliferation and tissue expression
of VEGF in a subgroup of primary mesothelioma samples
(Figures 2 and 3). Taken together, these data suggest that
inflammatory scores can stratify patients into different clini-
cal and biological categories, with diverse survival outcomes.
Indeed, the interplay between inflammation, angiogen-
esis, and cellular proliferation is a concept consolidated in
MPM. Previous studies have shown that tumor-secreted pro-
inflammatory cytokines correlate with clinical progres-
sion,31,32 promotion of angiogenesis,33 and suppression of
antitumor immune response.34 A number of studies have
considered the interplay between circulating proangiogenic
factors, including VEGF, and clinical outcome, with no
association reported.16,35 However, the reliability of circulat-
ing VEGF as a biomarker of angiogenesis is limited by
artifacts such as direct release from activated platelets and has
not been shown to be a reliable biomarker of angiogene-
sis.36,37 A number of studies have tried to elucidate the
individual cytokines driving the inflammatory response asso-
ciated with malignancy with inconclusive results.16,35 It is
likely that not one cytokine is involved, but that there is a
complex interplay of proinflammatory cytokines and growth
factors that is reflected by the mGPS and NLR. Therefore, our
data suggest that the mGPS and NLR may be more reliable
and reproducible surrogates of neoangiogenesis and prolifer-
ation in MPM. Although provocative, these results require
further validation.
On the basis of on our preliminary results, and of the
previously observed predictive value of inflammatory mark-
ers, we speculate that the mGPS and NLR may not only be
useful as a statistically validated tool to support patient
selection in clinical trials but also as pharmacodynamic bio-
markers in prospective studies evaluating novel experimental
therapies in MPM. Although these implications may not be
directly inferred by our retrospective study, the lack of
predictive markers of response to systemic treatment, espe-
cially in the context antiangiogenic treatments, encourages
further prospectively designed studies to further validate the
surrogate relationship between inflammatory indices and tu-
mor neoangiogenesis.
In conclusion, the choice between pursuing active an-
ticancer therapy rather than palliation of symptoms can be
challenging in MPM. Currently, treatment allocation in MPM
is dependent on a number of subjective parameters such as
PS.38 Our analysis of prognostic variables in a cohort of
patients with MPM validates the mGPS and NLR, but not the
PLR, as independent predictors of OS. Interestingly, our
results show that mGPS and NLR are superior to PS alone in
predicting patient’s survival. We also examined the EPS and
a number of other known prognostic parameters, but these
were not confirmed as independent prognostic factors on
multivariate analysis. The retrospective nature of our study,
and the significant amount of missing data from our cohort,
needs to be taken into consideration when considering these
findings. The time span of 18 years during which the study
was conducted could represent a source of heterogeneity in
our patient series as a result of the progressively improved
diagnostic and therapeutic management of MPM, especially
after the introduction of more effective agents such as pem-
etrexed. However, recent evidence suggests that the OS rates
TABLE 3. Clinicopathologic Features of the Patient
Subgroup Assessed by Immunohistochemistry
Variable Group A Group B p
Sex (male/female) 8/2 10/0 NS
Histologic subtype (epithelioid/
nonepithelioid)
9/1 6/4 NS
Stage (I–II/III–IV) 4/6 3/5a NS
ECOG PS (0/1) 8/2 2/8 0.007b
EPS (low/high risk) 8/2 4/6 NS
Overall survival, mo (median) 25.9 3.6 0.001b
a Missing data (n  2).
b Associations reaching statistical significance.
ECOG PS, Eastern Cooperative Oncology Group performance status; EPS, Euro-
pean Organization for the Research and Treatment of Cancer Prognostic Score.
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and the distribution of prognostic factors are not different in
patients treated before or after the introduction of pem-
etrexed.39 Moreover, we were unable to compare the utility of
the Cancer and Leukemia Group B prognostic score because
of incomplete clinical information. This would be an impor-
tant correlation in any future studies considering prognostic
variables in MPM. The expected contribution of a prognostic
marker is to facilitate and make the clinical assessment of the
patient’s prognosis more objective both in routine practice
and in clinical research. The desirable features of a stratifying
biomarker include reliability, reproducibility, inexpensive-
ness, and simplicity of use. The inflammatory-related mark-
ers, NLR and mGPS, are simple, validated, and universally
available biomarkers. Our results are provocative in suggest-
ing that the assessment of simple inflammatory tests could be
incorporated into routine clinical practice and in clinical
research to allow for accurate prognostication and identifica-
tion of subgroups of patients in whom active treatments can
be administered more safely or with better outcomes. Fur-
thermore, prospectively conducted studies are warranted to
validate the clinical applicability of these scores.
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